Comparison of dabigatran and warfarin anticoagulant therapy during catheter ablation in patients with atrial fibrillation
10.3969/j.issn.1008-0074.2018.01.17
- VernacularTitle:达比加群与华法令在心房颤动导管消融中抗凝治疗的对比研究
- Author:
Ying CHANG
1
;
Di PAN
;
Ting WANG
;
Xu-Bo WANG
;
Shu-Yan LI
Author Information
1. 一汽总医院心内科
- Keywords:
Atrial fibrillation;
Warfarin;
Catheter ablation
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2018;27(1):61-63
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare therapeutic effect and safety of dabigatran and warfarin anticoagulant therapy during catheter ablation in patients with atrial fibrillation (AF). Methods: Clinical data of 325 AF patients, who received catheter ablation in our hospital from Jan 2011 to Aug 2014, were retrospectively analyzed. According to perioperative anticoagulant therapy plan, patients were divided into dabigatran group (n=187) and warfarin group (n=138). General data, international normalized ratio (INR), activated coagulation time (ACT), success rate of pulmonary vein isolation (PVI), operation time and incidence rate of complications were compared between two groups. Results: Compared with warfarin group, there were significant reductions in percentages of diabetes mellitus (20. 3％ vs. 11. 8％), chronic heart failure (19. 6％ vs. 10. 2％) and left atrial diameter [(47±10) mm vs. (44± 9) mm]in dabigatran group, P＜0. 05 or＜0. 01. INR of dabigatran group was significantly lower than that of warfarin group [(1. 3±0. 3) vs. (2. 4±0. 4), P=0. 001], and there were no significant difference in ACT, success rate of PVI and operation time between two groups (P＞0. 05 all). Incidence rate of main complications in dabigatran group was significantly lower than that of warfarin group (0. 5％ vs. 5. 1％, P=0. 025). Conclusion: Compared with warfarin, there is significant reduction in INR and incidence rate of main complications during catheter ablation in dabigatran group, which is worth extending.
